An Antarctic expedition cruise that promised glaciers and penguin colonies has instead become the center of an international disease investigation. Three passengers from the MV Hondius are dead, and health authorities in five countries are tracking 11 hantavirus cases tied to the voyage, all caused by the Andes virus, the only hantavirus known to spread, in rare circumstances, from person to person.
As of May 14, 2026, the case count has held steady: eight laboratory-confirmed Andes virus infections, two probable cases, and one result that remains inconclusive. The World Health Organization, the U.S. Centers for Disease Control and Prevention, and the European Centre for Disease Prevention and Control have each issued guidance shaped by the same uncomfortable fact: while most hantaviruses are dead-end infections in humans, Andes virus has a documented, if limited, ability to jump between people in close quarters.
What the confirmed data shows
The WHO’s Disease Outbreak News report, dated May 13, 2026, records three deaths among the 11 identified cases. Laboratory confirmation and genomic identification were carried out at South Africa’s National Institute for Communicable Diseases (NICD) using Andes virus-specific sequencing. That work established the pathogen’s identity with high confidence, though the full genomic sequences have not yet been deposited in any public repository.
The WHO’s working hypothesis centers on an initial rodent exposure event aboard or near the vessel, likely during one of the shore excursions that are a hallmark of Antarctic expedition cruises. Andes virus circulates in wild rodent populations in southern South America, and passengers on these voyages routinely visit landing sites in Patagonia and the sub-Antarctic islands where the virus is endemic. No environmental sampling data from the ship or from excursion sites has been made public.
The CDC defines anyone who was onboard MV Hondius during the exposure window as having “high risk” exposure. Its interim clinical guidance calls for symptom monitoring, isolation of symptomatic individuals, airborne infection isolation rooms, and full personal protective equipment for healthcare workers treating suspected cases. The agency’s public statement describes the risk to the broader U.S. population as “extremely low,” a risk-communication judgment that reflects the small number of exposed individuals and the limited efficiency of human-to-human spread rather than a guarantee that no further cases will emerge.
Why person-to-person spread matters here
Most hantaviruses, including Sin Nombre virus in North America, do not pass between people. Andes virus is the exception. The WHO’s contact management guidance states that the virus “has been associated with limited human-to-human transmission, usually linked to close and prolonged contact.” That language rests on more than two decades of peer-reviewed research from Argentina, where nearly all documented person-to-person clusters have occurred.
A 1997 study published in the journal Virology provided the first molecular sequencing evidence consistent with interhuman transmission during an outbreak in southern Argentina. A subsequent investigation in Emerging Infectious Diseases analyzed multiple clusters and found that transmission was most likely during the prodromal phase and early illness, particularly among people in prolonged close contact. A 2014 Argentine cluster, also published in Emerging Infectious Diseases, used whole-genome sequencing to demonstrate 100% nucleotide identity across full viral genomes between linked patients, building one of the strongest molecular cases yet for person-to-person spread.
A cruise ship, with shared cabins, communal dining, and limited ventilation in interior spaces, is exactly the kind of enclosed environment those studies flag as highest risk. That is why the CDC’s operational posture toward individual passengers is considerably more cautious than its reassuring public messaging might suggest.
What remains unknown
Several critical gaps persist. No public records detail the specific chain of transmission aboard MV Hondius. Contact tracing logs have not been released by any investigating agency. Without published environmental sampling, it is impossible to determine whether one passenger contracted the virus from a rodent and then passed it to others in the ship’s confined spaces, or whether multiple passengers were independently exposed to the same environmental source during a shore excursion.
The genomic data that could resolve that question has not been made public. If all patient samples show nearly identical viral sequences, that would support a single introduction followed by limited person-to-person spread. Greater genetic diversity would point toward multiple independent rodent exposures. Past Argentine outbreaks relied on exactly this kind of full-genome comparison to distinguish transmission chains from shared environmental sources, and its absence here leaves a significant gap.
The ECDC flagged in its Early Warning and Response System assessment that human-to-human transmission of Andes virus is rare but documented, yet stopped short of concluding it occurred in this cluster. The WHO’s language is similarly careful, framing guidance around the virus’s known biological capacity rather than confirmed transmission aboard the ship. The distinction carries real public health weight: a cluster driven by a single environmental exposure on a shore excursion would demand a different response than one fueled by person-to-person chains in shared cabins.
The full geographic distribution of cases also remains unclear. Passengers dispersed to at least five countries after disembarkation, but only some national health agencies have publicly disclosed their case investigations. Without a consolidated line list, it is difficult to assess whether the three deaths cluster by timing or location, or whether severe outcomes are spread across the affected countries.
What passengers and the public should understand
Andes virus causes hantavirus pulmonary syndrome, a disease that progresses from fever, muscle aches, and gastrointestinal symptoms to severe respiratory distress as the lungs fill with fluid. Historical case-fatality rates for hantavirus pulmonary syndrome range from roughly 30% to 40% in documented outbreaks, according to the Pan American Health Organization. Three deaths among 11 identified cases falls within that expected range, though the numbers are too small for meaningful statistical comparison. There is no approved antiviral treatment or vaccine; care is supportive, and early recognition is the single most important factor in survival.
The incubation period for Andes virus typically ranges from one to five weeks, which means the monitoring window for exposed passengers has not yet fully closed. The CDC recommends that anyone who develops symptoms consistent with hantavirus pulmonary syndrome seek medical attention immediately and inform providers of their travel history. The WHO’s contact management framework assigns the highest concern to cabin mates, household members, and intimate partners of confirmed cases, with lower but nonzero concern for passengers who shared only public spaces on the ship.
For the general public, the risk is negligible. Andes virus does not spread through brief encounters, outdoor interactions, or contaminated surfaces. The documented pattern of transmission requires prolonged, close contact in enclosed settings. Broad quarantine of all returning travelers has not been recommended by any agency, and the targeted approach of monitoring close contacts and isolating symptomatic individuals aligns with what the science supports.
What comes next
The WHO has indicated it will continue to update its Disease Outbreak News page as new information becomes available. The release of full genomic sequences from the NICD, if and when it happens, will be the single most clarifying piece of evidence for understanding how this cluster unfolded. National health authorities in the five affected countries are expected to continue monitoring exposed passengers through at least early June 2026, when the outer edge of the incubation window will have passed for the last travelers to disembark.
For now, the most defensible reading of the evidence is that this is a serious but contained event: a rare and dangerous pathogen, a small and traceable cohort of exposed travelers, and a set of public health tools, including contact tracing, clinical monitoring, and clear communication about early symptoms, that offer a realistic path to limiting further spread. The case count has held at 11 for several days. Whether it stays there depends on data that has not yet been made public.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
